Novo Nordisk Opens the Largest Clinic for Children with Type 1 Diabetes in Bangladesh

Primary tabs

Novo Nordisk
Keywords: Community | Corporate Social Responsibility | Novo Nordisk | People | Positive Change | Social Development | Volunteerism & Community Engagement | access to health

Novo Nordisk Opens the Largest Clinic for Children with Type 1 Diabetes in Bangladesh

Novo Nordisk's Changing Diabetes® in Children programme achieves another victory in the treatment for children with type 1 diabetes in least developed countries.
tweet me:
Novo Nordisk open the largest clinic for children with type 1 #diabetes in Bangladesh http://3bl.me/tx8qmg #sustainability #access
Press Release
Monday, March 19, 2012 - 12:15pm

(3BL Media) March 19, 2012 - Dhaka: Novo Nordisk is now opening the largest clinic in its Changing Diabetes® in Children programme aimed at providing treatment for children with type 1 diabetes in least developed countries.

“Currently, 40% of all people living with diabetes in least developed countries reside in Bangladesh. If we take into consideration the poor settings and the significant prevalence of diabetes, Bangladesh is an incredibly important country for us to learn how to work through partnerships to ease the lives of the millions of patients here”, says Jesper Høiland, senior vice president of Novo Nordisk’s International Operations.

The new children’s clinic is part of the BIRDEM Hospital (Bangladesh Institute for Research in Diabetes, Endocrinology and Metabolism) and includes four separate clinical rooms for testing and treatment as well as a conference hall for training activities for healthcare professionals and educational sessions for families about disease management. In due course the clinic aims to enrol 1,500 children with diabetes, which will make it the largest clinic in the programme.

To read more, click here.

 

About Novo Nordisk

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,700 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. Novo Nordisk is listed in the 2011 Dow Jones Sustainability Indices with a gold class rating. For more information, visit novonordisk.com/sustainability.

 

Contact Information:

Charlotte Zarp-Andersson

Novo Nordisk

+45 3079 7603

czpa@novonordisk.com